VolitionRx – executive interview

Published on 16 July 2020

VolitionRx is a life sciences company developing novel, simple-to-use, blood-based tests to diagnose a broad range of cancers and other conditions by identifying and measuring nucleosomes in the blood stream. The primary focus is to develop the Nu.Q™ family of blood-based diagnostics tests for colorectal cancer.

In this video, VolitionRx chief executive officer Cameron Reynolds and chief scientific officer Dr Jake Micallef discuss VolitionRx’s recent results for its novel COVID-19 triage test. Based on the promising results using its Nu.Q™ assays in two pre-clinical studies, the company believes that measuring nucleosome presence could serve as a guiding biomarker for disease severity in COVID-19-positive patients.

Share this with friends and colleagues